Trial Profile
A Phase I Single Ascending Dose Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Remimazolam Besylate injection in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jan 2020
Price :
$35
*
At a glance
- Drugs Remimazolam (Primary) ; Midazolam
- Indications Anaesthesia; Sedation
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2019 Results evaluating the safety, pharmacokinetic (PK) and pharmacodynamic (PD) properties of remimazolam besylate following single ascending dose (SAD) and continuous infusion in healthy Chinese volunteers published in the European Journal of Clinical Pharmacology
- 07 Oct 2016 New trial record